Showing results (571-580 of 588) with videos related to

Sort By:
Pageof 59
Cardiology and Therapy|November 6, 2024
Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in IndiaUday M Jadhav, Saumitra Ray, T Govindan Unni, et al.
Molecular Psychiatry|June 17, 2025
Cell autonomous microglia defects in a stem cell model of frontotemporal dementia tauAbhirami K Iyer, Lisa Vermunt, Farzaneh S Mirfakhar, et al.
Journal of Medicinal Chemistry|March 5, 2020
Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple MyelomaJoshua D Hansen, Matthew Correa, Mark A Nagy, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
Plasma proteomics reveals divergent sex-specific senescence and bone biology signatures across neurodegenerative diseasesSiddharth Kaipa, Ting Zhai, Sai Rama Krishna Meka, et al.
Blood|May 24, 2015
CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCLPatrick R Hagner, Hon-Wah Man, Celia Fontanillo, et al.
Molecular Cancer Therapeutics|April 10, 2015
CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo CharacterizationDeborah S Mortensen, Kimberly E Fultz, Shuichan Xu, et al.
Blood|June 29, 2026
NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple MyelomaBo Hu, Jacob Edwards, Hardik Modi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2025
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancerSurendra Nayak, John D Norris, Massimo Ammirante, et al.
Blood Cancer Discovery|November 3, 2025
Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell LymphomaZhongying Mo, Lynda Groocock, Scott Wood, et al.
Pageof 59